Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**olanzapine + carbamazepine** is a combination of two small-molecule pharmaceutical drugs: olanzapine, an atypical antipsychotic, and carbamazepine, an anticonvulsant and mood stabilizer. This combination is sometimes used in the clinical management of manic or mixed episodes in bipolar disorder, typically when monotherapy is insufficient. Olanzapine acts chiefly as an antagonist at several neurotransmitter receptors including dopamine D2 and serotonin 5-HT2A, whereas carbamazepine stabilizes neuronal membranes by inhibiting voltage-gated sodium channels and also induces several cytochrome P450 enzymes, notably CYP1A2 and CYP3A4. The pharmacokinetic interaction is significant: carbamazepine induces olanzapine metabolism, reducing olanzapine plasma concentrations, potentially lowering therapeutic efficacy. Combination therapy may have additive effects on mood stabilization but is associated with increased risk of weight gain and metabolic disturbances[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on olanzapine + carbamazepine.